US76029N1063 - Common Stock - After market: 17.27 0 (0%)
NASDAQ:REPL (9/30/2022, 7:00:02 PM)+0.65 (+3.91%)
|GICS Sector||Health Care|
|Earnings (Last)||08-04 2022-08-04/bmo||Earnings (Next)||11-02 2022-11-02|
|Ins Owners||18.68%||Inst Owners||82.25%|
Find more stocks on Nasdaq
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
Replimune Group, Inc. is a clinical-stage biotechnology company, which engages in the development of oncolytic immunotherapy product candidates through immulytic platform. The company is headquartered in Woburn, Massachusetts and currently employs 206 full-time employees. The company went IPO on 2018-07-20. The firm is advancing a pipeline of tumor-directed oncolytic immunotherapies derived from its RPx platform to fill unmet need across cancer types. The firm's lead product candidate, RP1, is a selectively replicating version of HSV-1 that expresses GALV-GP R and human GM-CSF. RP1 is designed to treat more immune responsive tumor types. The firm's pipeline product candidates include RP2 and RP3. The encoded GALV-GP R protein enhances the tumor killing ability of the virus and increases immunogenic cell death. RP2 is an additionally encodes an anti-CTLA-4 antibody has designed to treat more immunologically silent tumors. RP3 expresses a pair of immune costimulatory pathway activating ligands, CD40L and 4-1BBL, to further increase the potency of the immune responses to treat immunologically cold tumors.
REPLIMUNE GROUP INC
500 Unicorn Park Dr
Woburn MASSACHUSETTS 01801
CEO: Philip Astley-Sparke
Target enrollment of 180 patients reached in the CERPASS randomized controlled registration-directed clinical trial evaluating RP1 in cutaneous squamous...
WOBURN, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development...
WOBURN, Mass., June 03, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development...
Presentations include recently updated results from the skin cancer cohort of IGNYTE, an ongoing Phase 1/2 study of RP1 combined with Opdivo® (nivolumab),...
Enrollment in the CERPASS clinical trial with RP1 in cutaneous squamous cell carcinoma (CSCC) expected to be completed in mid-year 2022; top line data...
Here you can normally see the latest stock twits on REPL, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.